Stock market hits all-time high
Digest more
While it may not be a steal of a deal, with the business on the cusp of some exciting growth, Johnson & Johnson's stock could prove to be a good long-term buy. It's already seen as a safe-haven type of stock to own, as it pays a solid dividend that yields 2.3%. Adding more growth to the mix could help it soar higher in the years ahead.
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)’s stock experienced a remarkable 52% increase, driven
Zacks Investment Research on MSN
Johnson & Johnson (JNJ) is attracting investor attention: Here is what you should know
Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
After a strong performance in 2025, Johnson & Johnson is starting the new year right.
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience.
Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s radar. During the episode, Cramer discussed the company’s earnings and the following market reaction, as he stated: Alright, what do we make of these earnings from Johnson & Johnson?
Johnson & Johnson (NYSE: JNJ) is a big name in healthcare. People all over the world are familiar with the brand of Johnson & Johnson. And investors have grown to love its dividend, which the company has been increasing for 61 consecutive years. Twenty ...
Johnson & Johnson is a picture of stability.
Healthcare may be entering early mean reversion, but much of Johnson & Johnson’s valuation recovery has already occurred. Post-Kenvue, JNJ is a higher-growth, less dividend-centric business, changing how income investors should evaluate the stock.
Hindsight is always 20/20, and nowhere is this more evident than in the stock market. But that doesn’t stop investors from trying to determine what they would have made if they had actually invested in a stock they were considering. With this in mind, if ...
Johnson & Johnson (NYSE:JNJ) is among the most profitable healthcare stocks to buy. On January 22, TD Cowen lifted the price target on Johnson & Johnson (NYSE:JNJ) to $250, up from $222, and maintained a Buy rating,